Covid-19 Test Management Platform

Covid-19 Test Management Platform是一个基于分布式账本技术（DLT）的统一平台，面向试剂盒供应商、实验室、数据科学家、公共卫生从业者和政策制定者。它将由一个基于移动的应用程序、桌面控制台和平台组成，集成在一起，提供一个整理、管理、记录和向用户提供测试数据的端到端过程。测试管理平台提供了测试的全过程和参与各方的沟通渠道。这将有助于国家，个人和公司作为一个整体。该系统将利用快速DLT提供的不变性，可用性和帐户结构来提供：1.稳定的数据，一旦上传，即不可变和匿名2。选定的数据访问权限-用户将能够根据帐户权限选择性地委派对其测试数据的访问权限3。检测试剂盒供应商将能够跟踪每个检测试剂盒端到端4。实验室将能够安全、快速地将测试结果直接发送到用户的应用程序帐户5。分布式账本的连通性允许系统的大规模部署，而不会增加成本。该平台将通过安全的互联网连接6进入。选择的DLT是快速的，可扩展的，具有免费的交易和数据记录，利用现成的服务器，这些服务器不像当前的区块链挖掘节点那样能源密集。该平台适用于任何测试，因此可重复使用，最小的重新配置要求。我们认为，该平台将对通过测试、理解和开发COVID-19疫苗和疗法进行跟踪的合作努力产生积极影响。这一平台还可以成为跟踪其他大流行病和传染病的基础。

Covid-19 Test Management PlatformIs a distributed ledger technology (DLT) based unified platform for test kit suppliers, laboratories, data scientists, public health practitioners and policymakers. It will consist of a mobile based application, desktop consoles and platform integrated together to deliver an end to end process of collating, managing, recording and delivering test data to users. The test management platform provides the whole process of testing and a channel for the parties included. This will help the nation, individuals and companies as a whole.The system will leverage the immutability, availability and account structures offered by a fast DLT to offer:1. Stable data that is immutable and anonymous once uploaded2. Selected access to data - Users will be able to selectively delegate access to their test data based on account permissions3. Test kit suppliers will be able to track each test kit end to end4. Laboratories will be able to deliver test results securely and quickly directly to the user's application account5. The connectedness of the Distributed Ledger allows for large scale rollout of the system without accelerating costs. The platform will be accessible through secure internet connections6. The selected DLT is fast, scalable with free transactions and data recording, utilising off the shelf servers that are not as energy intensive as current blockchain mining nodesThe platform is suitable for any testing and is therefore reusable with minimum reconfiguration requirement. We submit that this platform will have a positive impact on the collaborative effort of tracking through testing, understanding and the development of vaccines and therapies for COVID-19\. This platform can also form the basis of tracking other pandemics and infectious diseases.